投资
80年投资退出
21基金
6想告知投资者类似MVM的合作伙伴关于你的公司吗?
提交你的分析师简报在投资者面前,CB Insights的平台上的客户和合作伙伴。德赢体育vwin官方网站
最新的MVM的合作伙伴新闻
2023年3月28日
C系列GT医疗技术提出了4500万美元的超额认购融资由Gilde医疗/融资将帮助扩大GammaTile®治疗新诊断的患者和脑部肿瘤复发坦佩亚利桑那。,March 23, 2023 /PRNewswire/ — GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that it has raised $45 million in a Series C financing led by Gilde Healthcare Partners with participation from existing institutional investors MVM Partners, MedTech Venture Partners, and BlueStone Venture Partners. Funds from this round will support the expanded commercialization of GammaTile Therapy, an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with operable brain tumors. In addition, the funding will support its clinical study plans to further validate improvements in overall survival, progression-free survival, and quality of life for patients with brain metastases, glioblastomas, and meningiomas. “We are excited that this funding will help us reach more patients with operable brain tumors,” said Matthew Likens, president, and CEO of GT Medical Technologies. “GammaTile is an important innovation for these patients who need better treatment options. Unlike traditional radiation therapy, which cannot be initiated until several weeks after brain tumor removal surgery, STaRT enables patients to begin receiving radiation treatment at the time of their tumor removal surgery. This gives patients a head start against tumor regrowth.” “Our focus is making state-of-the-art medical advancements like GammaTile more available to patients to address unmet clinical needs and ultimately improve the standard of care. It’s gratifying to know that we’re enabling GT Medical Technologies to improve the lives of more patients with brain tumors,” commented Geoff Pardo, General Partner, Gilde Healthcare Partners. “We are impressed by the company’s strong commercial traction. Our confidence in the business led us to invest above our current ownership level, and we are excited by the opportunity to help make GammaTile transform the standard of care for patients with brain tumors,” added Kyle Dempsey, Partner of MVM Partners and GT Medical board member. GammaTile Therapy is a groundbreaking brain tumor treatment implanted at the completion of brain tumor removal surgery. GammaTile Therapy delivers immediate, targeted radiation helping to eradicate brain tumor cells before they can replicate post-surgery. GammaTiles are bioresorbable collagen tiles embedded with radiation sources. This latest advancement in brain tumor treatment has shown favorable clinical outcomes in patients with glioblastomas, metastatic brain tumors, and aggressive meningiomas. About GT Medical Technologies, Inc. Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. FDA-cleared GammaTile is a Surgically Targeted Radiation Therapy (STaRT) that treats patients with newly diagnosed malignant and recurrent brain tumors. This “one-and-done” treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives, without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 80 hospitals, with more centers being added each month. For more information, visit www.gtmedtech.com and follow @GammaTile on Twitter and LinkedIn . About Gilde Healthcare Partners Gilde Healthcare is a specialized healthcare investor managing over $2B across two fund strategies: venture & growth capital and private equity. The Venture & Growth fund of Gilde Healthcare invests in fast growing companies active in therapeutics, digital health and medtech. The venture & growth companies are based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com . About MVM Partners MVM has invested in high-growth healthcare businesses since 1997. The firm has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, digital health, and other sectors of healthcare. For more information, visit the company’s website at MVM.com . Media contact:
MVM伙伴投资
80年投资
MVM的合作伙伴了80年投资。他们最新的投资GT医疗技术作为他们的一部分C系列在2023年3月3日。
MVM伙伴投资活动
日期 |
轮 |
公司 |
量 |
新的吗? |
共同投资者 |
来源 |
---|---|---|---|---|---|---|
3/23/2023 |
C系列 |
GT医疗技术 |
45美元 |
没有 |
8 |
|
10/17/2022 |
C系列 |
欧塞奥 |
38.5美元 |
是的 |
MVM的合作伙伴,和未披露的投资者 |
6 |
9/12/2022 |
E系列 |
Neurolens |
67美元 |
是的 |
4 |
|
2/18/2022 |
D系列 |
|||||
1/7/2022 |
E系列 |
日期 |
3/23/2023 |
10/17/2022 |
9/12/2022 |
2/18/2022 |
1/7/2022 |
---|---|---|---|---|---|
轮 |
C系列 |
C系列 |
E系列 |
D系列 |
E系列 |
公司 |
GT医疗技术 |
欧塞奥 |
Neurolens |
||
量 |
45美元 |
38.5美元 |
67美元 |
||
新的吗? |
没有 |
是的 |
是的 |
||
共同投资者 |
MVM的合作伙伴,和未披露的投资者 |
||||
来源 |
8 |
6 |
4 |
MVM的合作伙伴投资退出
21组合退出
MVM的合作伙伴有21投资组合出口。他们最新的投资退出病人连接 在2021年12月22日。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自国家申请或者新闻,由VentureSource的提供,或基于比较数据的估值模型。
|
收购者 |
来源 |
---|---|---|---|---|---|
12/22/2021 |
收购了 |
1 |
|||
11/4/2021 |
IPO——二世 |
公共 |
6 |
||
1/5/2021 |
收购了 |
17 |
|||
日期 |
12/22/2021 |
11/4/2021 |
1/5/2021 |
||
---|---|---|---|---|---|
退出 |
收购了 |
IPO——二世 |
收购了 |
||
公司 |
|||||
估值 |
|||||
收购者 |
公共 |
||||
来源 |
1 |
6 |
17 |
MVM的合作伙伴收购
1收购
MVM的合作伙伴收购了1 公司。他们最新的收购AmbioPharm 在2014年11月20日。
日期 |
投资阶段 |
公司 |
估值
提交的估值公司,采自国家申请或者新闻,由VentureSource的提供,或基于比较数据的估值模型。
|
总资金 |
请注意 |
来源 |
---|---|---|---|---|---|---|
11/20/2014 |
私人股本 |
|
Acq -鳍 |
2 |
日期 |
11/20/2014 |
---|---|
投资阶段 |
私人股本 |
公司 |
|
估值 |
|
总资金 |
|
请注意 |
Acq -鳍 |
来源 |
2 |
MVM的合作伙伴基金的历史
6基金历史
MVM的合作伙伴有6 基金,包括MVM六世。
截止日期 |
基金 |
基金类型 |
状态 |
量 |
来源 |
---|---|---|---|---|---|
11/14/2022 |
MVM六世 |
|
|
500美元 |
1 |
1/8/2020 |
MVM V |
||||
5/3/2016 |
MVM四世 |
||||
1/1/2008 |
MVM基金III |
||||
1/1/2002 |
MVM国际生命科学基金 |
截止日期 |
11/14/2022 |
1/8/2020 |
5/3/2016 |
1/1/2008 |
1/1/2002 |
---|---|---|---|---|---|
基金 |
MVM六世 |
MVM V |
MVM四世 |
MVM基金III |
MVM国际生命科学基金 |
基金类型 |
|
||||
状态 |
|
||||
量 |
500美元 |
||||
来源 |
1 |
MVM的合作伙伴团队
1团队成员
MVM的合作伙伴有1 团队成员,包括当前的创始合伙人,斯蒂芬·里德。
的名字 |
工作经历 |
标题 |
状态 |
---|---|---|---|
斯蒂芬•里德 |
|
创始合伙人 |
当前的 |
的名字 |
斯蒂芬•里德 |
---|---|
工作经历 |
|
标题 |
创始合伙人 |
状态 |
当前的 |
发现正确的解决方案为您的团队
CB见解德赢体育vwin官方网站科技市场情报平台分析数百万数据点在供应商、产品、合作关系,专利来帮助您的团队发现他们的下一个技术解决方案。